Edition:
India

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

80.98USD
19 Jan 2018
Change (% chg)

$-0.19 (-0.23%)
Prev Close
$81.17
Open
$81.30
Day's High
$81.52
Day's Low
$80.37
Volume
2,741,842
Avg. Vol
2,666,630
52-wk High
$86.26
52-wk Low
$63.76

Latest Key Developments (Source: Significant Developments)

Kite Announces Clinical Collaboration With Pfizer
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Gilead Sciences Inc ::KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA.GILEAD SCIENCES INC - KITE ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH PFIZER, INC.GILEAD SCIENCES INC - MULTI-CENTER PHASE 1/2 STUDY SPONSORED BY KITE IS EXPECTED TO BEGIN IN 2018.GILEAD SCIENCES INC - RESULTS OF STUDY WILL BE USED TO EVALUATE OPTIONS FOR FURTHER DEVELOPMENT OF THE COMBINATION, OR SIMILAR COMBINATIONS.  Full Article

Teva Announces Exclusive Launch Of Generic Viread® In The United States
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIREAD® IN THE UNITED STATES.TEVA ANNOUNCES EXCLUSIVE LAUNCH OF GENERIC VIREAD® IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ANNOUNCED EXCLUSIVE LAUNCH OF GENERIC VIREAD TABLETS 300 MG IN U.S..  Full Article

Gilead Sciences and Kite To Acquire Cell Design Labs
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND KITE TO ACQUIRE CELL DESIGN LABS.GILEAD SCIENCES INC - DEAL FOR UP TO APPROXIMATELY $567 MILLION.GILEAD SCIENCES INC - AGREEMENT INCLUDES AN INITIAL UPFRONT PAYMENT OF APPROXIMATELY $175 MILLION.GILEAD SCIENCES - DEAL INCLUDES ADDITIONAL PAYMENTS OF UP TO $322 MILLION PAID TO SHAREHOLDERS OF CELL DESIGN LABS OTHER THAN KITE UPON OCCURRENCE OF CERTAIN EVENTS.GILEAD SCIENCES - CO, CELL THERAPY UNIT KITE ANNOUNCED THEY ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH THEY AGREED TO ACQUIRE CELL DESIGN LABS.GILEAD SCIENCES - WILL BUY ALL OF CELL DESIGN LABS' SHARES, WHICH INCLUDES ABOUT 12.2 PERCENT OF SHARES OF CELL DESIGN LABS CURRENTLY HELD BY KITE.  Full Article

X-Chem And Gilead Announce Drug Discovery Collaboration
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Gilead Sciences Inc ::X-CHEM AND GILEAD ANNOUNCE DRUG DISCOVERY COLLABORATION.‍X-CHEM-AS PER AGREEMENT, CO TO SCREEN PROPRIETARY DEX(TM) LIBRARIES TO DISCOVER THERAPEUTIC LEADS AGAINST TARGETS IN ANTIVIRAL, ADDITIONAL THERAPEUTIC AREAS​.X-CHEM- ‍UNDER TERMS ,CO TO RECEIVE UPFRONT PAYMENT, POTENTIAL LICENSING FEES,& ADDITIONAL PAYMENTS.X-CHEM​- GILEAD ‍HAS OPTION TO LICENSE DRUG LEADS DISCOVERED UNDER COLLABORATION, FOR FURTHER DEVELOPMENT, COMMERCIALIZATION OF RESULTING PROGRAMS.  Full Article

Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial
Thursday, 16 Nov 2017 

Nov 15 (Reuters) - Spring Bank Pharmaceuticals Inc :Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve trial.Spring Bank Pharmaceuticals - ‍Inarigivir 50mg daily for 12 weeks met both primary endpoints of safety and efficacy in second cohort of achieve trial​.Spring Bank Pharmaceuticals - ‍inarigivir demonstrated a statistically significant reduction in hbv dna at week 12 compared to combined placebo group​.Spring Bank Pharma - sees Gilead initiating Phase 2 trial examining co-administration of inarigivir, vemlidy​ for infections with chronic HBV in Q1 2018.  Full Article

Gilead sciences says post-trial motions judge denied Idenix’S motion for enhanced damages
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Gilead Sciences Inc :Gilead Sciences says in Sept 2017, post-trial motions judge denied Idenix’s motion for enhanced damages and attorney’s fees - SEC filing.Gilead Sciences Inc - expect the judge to rule on outstanding motions with relation to Idenix in late 2017 or early 2018‍​.  Full Article

Gilead announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Gilead Sciences Inc ::Announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis (NASH).In Phase 2 study, ‍oral ACC inhibitor led to significant reductions in measures of liver fat and fibrosis​.In Phase 2 study, GS-0976 was well-tolerated; nausea, abdominal pain & diarrhea were most common adverse events​.Differences between GS-0976 5 mg and placebo were not statistically significant​.  Full Article

FDA approves Gilead's CAR-T cell therapy
Thursday, 19 Oct 2017 

Oct 18 (Reuters) - U.S. Food and Drug Administration -:FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma.FDA says granted approval of Yescarta to Kite Pharma Inc.FDA says Yescarta carries a boxed warning for Cytokine release syndrome‍​.FDA says due to risk of CRS and neurologic toxicities, Yescarta is being approved with risk evaluation and mitigation strategy.FDA says it is requiring that hospitals and their associated clinics that dispense Yescarta be specially certified.  Full Article

U.S. FDA approves Gilead’s Vosevi for re-treatment of adults with chronic hepatitis C virus
Tuesday, 18 Jul 2017 

July 18 (Reuters) - Gilead Sciences Inc :U.S. Food and Drug Administration approves Gilead’s Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for re-treatment of adults with chronic hepatitis C virus.Vosevi has a boxed warning in its product label regarding risk of hepatitis B virus (HBV) reactivation in HCV/HBV coinfected patients.Vosevi's approval is based on data from phase 3 polaris-1 and polaris-4 studies.  Full Article

Gilead sciences, WHO announce 5-year visceral leishmaniasis collaboration
Wednesday, 28 Sep 2016 

Gilead Sciences : Gilead Sciences and the World Health Organization announce five-year visceral leishmaniasis collaboration . Partnership with World Health Organization to expand access to diagnostic services and treatment for visceral leishmaniasis .Gilead donates $20 million to enhance access to treatment for often fatal neglected tropical disease.  Full Article

BRIEF-Kite Announces Clinical Collaboration With Pfizer

* KITE ANNOUNCES CLINICAL COLLABORATION TO EVALUATE INVESTIGATIONAL COMBINATION OF YESCARTA™ (AXICABTAGENE CILOLEUCEL) AND PFIZER’S UTOMILUMAB IN LARGE B-CELL LYMPHOMA